Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

June 17, 2025

Study Completion Date

June 17, 2025

Conditions

Type 2 Diabetes MellitusWeight Loss

Interventions

DRUG

[14C]HRS9531

A single dose of \[14C\]HRS9531 injected subcutaneously.

Trial Locations (1)

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY